increased intestinal adenocarcinoma incidence_Smad3<tm1Cxd>/Smad3<tm1Cxd>

http://metadb.riken.jp/0002957EI129S6SvEvTacC57BL6orI129S6SvEvTacNIHBlackSwissSmad3tm1CxdSmad3tm1CxdSmad3tm1Cxd

increased intestinal adenocarcinoma incidence_Smad3<tm1Cxd>/Smad3<tm1Cxd>

表現型アノテーション

MGI marker

http://metadb.riken.jp/db/mgi_rdf/variant_of

• SMAD family member 3
  http://metadb.riken.jp/db/mgi_rdf/MGI:1201674

遺伝子型

http://metadb.riken.jp/db/mgi_rdf/allele_composition

• Smad3<tm1Cxd>/Smad3<tm1Cxd>

アレルシンボル

http://metadb.riken.jp/db/mgi_rdf/allele_symbol

• Smad3<tm1Cxd>

遺伝的背景

http://metadb.riken.jp/db/mgi_rdf/genetic_background

• either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss)

MP annotation

http://metadb.riken.jp/db/bioresource_schema/brs_indicatesPhenotype

• increased intestinal adenocarcinoma incidence
  http://purl.obolibrary.org/obo/MP_0002957

文献

http://purl.org/net/cito/citesAsAuthority

• X. Yang, et.al., Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta., The EMBO journal, 1999, 18
  http://rdf.ncbi.nlm.nih.gov/pubmed/10064594